Unmet Need

With so many people who may benefit from a PrEP medication, why aren’t more being prescribed one?

Learn about HIV prevalence and risk factors.

Uptake of PrEP medication use in the United States remains low despite significant HIV risk1

Nearly
1 million
cisgender males had an indication
for a PrEP medication as of June 2021

Icon for total cisgender males indicated for PrEP (pre-exposure prophylaxis) and those with prescription.

However, only ~24%
of these individuals were prescribed
a PrEP medication2

According to the CDC, HIV risk remains high among Black and Latinx MSM populations3,4

Among MSM diagnosed with HIV in 2019,5

38%

were Black MSM

and

32%

were Latino MSM

Yet, in a 2017 CDC study of PrEP medication use among MSM at risk (n=4056), only6

6%

were Black MSM

and

8%

were Latino MSM

Transgender women who are at risk for HIV may benefit from PrEP medication

A study conducted between 2019 and 2020 in Atlanta, Los Angeles, New Orleans, New York City, Philadephia, Seattle, and San Francisco (n=1608) found that

42%

(n=659/1561) of TGW were HIV positive

and only

32%

(n=288/902) of HIV-negative TGW were on a PrEP medication7

Individuals who use PrEP medication inconsistently may have increased risk of acquiring HIV8

In a real-world study of PrEP medication users from 2012 to 2018 in San Francisco, CA (N=986), seroconversions among participants who stopped their PrEP medication saw a

7.5-fold increase

compared with participants who continued using their PrEP medication9

Take an active role—be the connection between appropriate individuals at risk of HIV and the initiation of a PrEP medication.

CDC=Centers for Disease Control and Prevention; MSM=men who have sex with men; TGW=transgender women (who have sex with men).